Newsroom

AURORA, Colo.--(BUSINESS WIRE)--Avant-garde Health, the leading provider of solutions for improving perioperative quality and efficiency, is working with UCHealth to align its teams and strengthen performance under the CMS Transforming Episode Accountability Model (TEAM), Medicare’s mandatory bundled payment model for five common surgical episodes. “Providing the highest quality care and best outcomes is always our top priority,” said Danielle Andrade, UCHealth vice president of care continuum...

LONDON--(BUSINESS WIRE)--  DB ETC PLC Dated: 07 July 2026 COMPANY ANNOUNCEMENT Immediate Release 07 July 2026 DB ETC plc (the Issuer) (incorporated and registered in Jersey under the Companies (Jersey) Law 1991 (as amended) with registered number 103781) Re: Value per Security of ETC Securities Announcement The Issuer is providing the Value per Security for the ETC Securities for the following Series as set out in the table below for 06 July 2026 Series ISIN Currency Value per Security Series 0...

TEMPLE, Texas--(BUSINESS WIRE)--McLane Engage 2026 to feature global AI expert keynote, new Supplier Summit and product innovation....

マサチューセッツ州レキシントン--(BUSINESS WIRE)--（ビジネスワイヤ） -- 免疫腫瘍学のイノベーションをリードするアジーナス（Agenus Inc.）（Nasdaq：AGEN）は、活動性肝転移を伴わない難治性マイクロサテライト安定性（MSS）転移性大腸がん（mCRC）患者を対象に、Fc強化型の多機能抗CTLA-4抗体であるボテンシリマブ（BOT）と抗PD-1抗体であるバルスチリマブ（BAL）の併用を評価する、患者登録が完了した第1b相C-800-01コホートから得られた3年ランドマークデータを発表しました。本データは、ドイツ・ミュンヘンで開催された欧州臨床腫瘍消化器癌会議2026（European Society for Medical Oncology Gastrointestinal Cancers（ESMO GI）Congress 2026）で、7月2日に発表されました。 BOT+BALは、従来の免疫チェックポイント阻害薬によるベネフィットがこれまで限定的であり、標準療法で病勢進行した後には持続的な効果をもたらす治療選択肢が少ない、前治療歴の多い患者集団におい...

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), leader nell’innovazione in campo immuno-oncologico, ha annunciato oggi i dati di riferimento relativi alla fase 1b, raccolti nell’arco di tre anni, provenienti dalla coorte completa C-800-01, che valuta il botensilimab (BOT), un anticorpo anti-CTLA-4 multifunzionale potenziato con Fc, in combinazione con balstilimab (BAL), un anticorpo anti-PD-1, in pazienti affetti da carcinoma colorettale metastatico (mCRC) refrattario, co...

CARMEL, Ind.--(BUSINESS WIRE)--SEPRO Scientific™, formerly known as SePRO Corporation, today announced the launch of a comprehensive brand refresh that unifies the company’s Water and Land divisions under the SEPRO Scientific name. The evolution reflects the company’s continued focus on delivering customer value through science-led insights, digitally-integrated solutions, and measurable outcomes, while reinforcing its long-standing commitment to science as the foundation for solving complex en...

LEXINGTON, Massachusetts--(BUSINESS WIRE)--  Agenus présente à l’ESMO GI 2026 des données marquantes sur le traitement BOT+BAL, montrant un taux de survie globale à trois ans de 33 % chez les patients atteints d’un cancer colorectal métastatique réfractaire de type MSS sans métastases hépatiques actives Agenus Inc. (Nasdaq : AGEN), leader de l’innovation en immuno-oncologie, a annoncé aujourd’hui les données marquantes à trois ans de l’étude de phase 1b menées sur la cohorte C-800-01, dont le r...

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), ein Marktführer im Bereich der immunonkologischen Innovation, präsentierte heute wegweisende Daten aus der dreijährigen Phase-1b-Studie zur vollständig rekrutierten C-800-01-Kohorte, in der Botensilimab (BOT), ein Fc-verstärkter multifunktionalen Anti-CTLA-4-Antikörper, in Kombination mit Balstilimab (BAL), ein Anti-PD-1-Antikörper, bei Patienten mit refraktärem mikrosatellitenstabilem (MSS) metastasiertem Kolorektalkarzinom...

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), empresa líder en innovación en inmunooncología, anunció hoy los resultados a tres años de fase 1b de la cohorte completa C-800-01, que evalúa botensilimab (BOT), un anticuerpo anti-CTLA-4 multifuncional potenciado con Fc, en combinación con balstilimab (BAL), un anticuerpo anti-PD-1, en pacientes con cáncer colorrectal metastásico (mCRC) estable a nivel de microsatélites (MSS) y refractario, sin metástasis hepáticas activas....

RAPID CITY, S.D.--(BUSINESS WIRE)--Conti Federal Services LLC, a leading federal construction and design-build firm, has been awarded a $43.9M firm-fixed-price contract for the B-21 60 Row South Environmental Protection Shelters (EPS) at Ellsworth Air Force Base (AFB), South Dakota. Awarded by the U.S. Army Corps of Engineers (USACE) Omaha District, the shelters provide protection for the B-21 Raider, extending the life of the aircraft. Conti Federal’s scope of work includes the construction of...